Bessemer Group’s Neurogene NGNE Stock Holding History

Bessemer Group’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-87	Closed	-$2K	–	2652
2025 Q3	$2K	Buy	+87	New	+$1.75K	﹤0.01%	2337
2024 Q1	–	Sell	-20,000	Closed	-$388K	–	2150
2023 Q4	$388K	Buy	+20,000	New	+$286K	﹤0.01%	890

Other funds holding NGNE

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bessemer Group's NGNE Position: Q4 2025 in Review

Bessemer Group sold out of Neurogene (NGNE) in Q4 2025, closing a stake of 87 shares — an estimated $2K sold.

Bessemer Group first reported a position in NGNE in Q4 2023 and held it in 2 quarters. The position peaked at $388K in Q4 2023. 93 funds tracked by Wall St. Rank hold NGNE as of Q4 2025.

Bessemer Group reported no remaining Neurogene position as of Q4 2025 after selling out during the quarter.
Bessemer Group sold 87 Neurogene shares in Q4 2025, an estimated $2K.
Bessemer Group first reported a position in Neurogene in Q4 2023 and held it in 2 quarters.
Bessemer Group's Neurogene position peaked at $388K in Q4 2023.
93 funds tracked by Wall St. Rank held Neurogene as of Q4 2025.

Based on Bessemer Group's 13F filing for Q4 2025, filed 5 Feb 2026.